Harvard Pilgrim Signs Outcomes-Based Contracts with AstraZeneca
NEC member Harvard Pilgrim HealthCare recently signed two outcomes-based contracts with AstraZeneca for medicines used to treat Type 2 Diabetes and acute coronary disease.
Outcomes-based contracts allow Harvard Pilgrim to pay for the drugs based on their value to a patient rather than the amount of medicine provided by AstraZeneca. One of the contracts is for the drug Brilinta, which is used to lower the risk of a patient having another heart attack or dying from a heart attack. Doctors will monitor whether there is a reduction in patients hospitalized due to a repeat acute coronary event while using Brilinta. The other medicine Harvard Pilgrim signed a contract for is Bydureon, which is used to control a Type 2 Diabetes patient’s blood glucose levels. Doctors will measure the drug’s effectiveness by tracking if patients are able to reach a predetermined goal blood glucose level.
“Linking the ultimate cost of these medicines to their real-world clinical effectiveness really puts patients at the center of focus,” said Michael Sherman, Harvard Pilgrim’s Chief Medical Officer. “Real world performance may differ from what is observed in well-controlled clinical trials, and the willingness of pharmaceutical companies like AstraZeneca to go at risk for delivering on these outcomes sends a positive message to health plans, prescribing physicians, and patients.”
The New England Council congratulates Harvard Pilgrim on the signing of this new agreement that will benefit patients, physicians, and the company overall. Read more in Worcester Business Journal and Business Wire.
Recently from the Blog
CMBG3 to Host Webinar on California Prop 65 Changes